503a tirzepatide Best Compounded Pharmacy: 9 Still Legal (2026) Most Successful Weight Loss Program. Tirzepatide / Niacinamide Injection |

Tirzepatide, a dual GLP-1/GIP receptor agonist, offers an innovative approach to weight loss

The consistency across dose groups is telling

CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage

Orforglipron 3 mg dose: 4.7% weight loss Orforglipron 12 mg dose: 6.1% weight loss Orforglipron 36 mg dose: 7.9% weight loss Placebo: 1.6% weight loss When bodyweight was compared between groups, orforglipron demonstrated a greater reduction than placebo and other GLP-1 receptor agonists in similar studies

Patients have a choice when deciding where to source their GLP-1 medication

As patients lose weight and stabilize blood sugar levels, they may experience fewer nighttime awakenings